Research Article
Noninterventional Study of Transdermal Fentanyl (Fentavera) Matrix Patches in Chronic Pain Patients: Analgesic and Quality of Life Effects
Table 6
Summary of total adverse events during 2 months treatment with the transdermal fentanyl (Fentavera) patch.
| | |
| Preferred terms (MedDRA) | | Nausea | 6 | Vomiting | 3 | Vertigo | 2 | Restlessness | 2 | Abdominal pain upper | 2 | Fatigue | 1 | Sedation | 1 | Dysphoria | 1 | Retching | 1 | Feeling abnormal | 1 | Dyspnoea | 1 | Confusional state | 1 | Rash | 1 | Death | 1 | Dermatitis allergic | 1 | Pain | 1 | Diarrhoea | 1 | Swelling | 1 | Headache | 1 | Depressive symptom | 1 | System-Organ-Class (SOC) (MedDRA) | | Gastrointestinal disorders | 13 | General disorders and administration site conditions | 5 | Psychiatric disorders | 5 | Ear and labyrinth disorders | 2 | Nervous system disorders | 2 | Skin and subcutaneous tissue disorders | 2 | Respiratory, thoracic, and mediastinal disorders | 1 | Outcome | | Recovered | 16 | Unknown | 1 | Fatal | 1 | Life-threatening | 3 | Causality assessment | | Certain | 4 | Probable | 9 | Possible | 2 | Unlikely | 3 |
|
|